|
9th Influenza Conference 2023
The Ninth ESWI Influenza Conference: Highlights
ESWI 2023: 10 key take home messages
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part
Joint EMA-ECDC press briefing on current state of respiratory diseases and treatments in the EU/EEA
As autumn season approaches the EMA and ECDC held a press briefing to provide latest information on respiratory diseases as well as vaccines and treatments available
International scientific community gathers in Valencia for the 9th ESWI Conference on Influenza, COVID-19, and RSV
Since it was established 30 years ago, the European Scientific Working Group on Influenza and other Acute Respiratory Viruses (ESWI) is hosting the 9TH ESWI Influenza Conference
Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6
Although WHO has declared an end to the emergency phase of the COVID-19 pandemic, SARS-CoV-2 has continued to spread and evolve, giving rise to new variants.
The SARS-CoV-2 Spike Protein Mutation Explorer: using an interactive application to improve the public understanding of SARS-CoV-2 variants of concern
The rapid evolution of SARS-CoV-2 resulted in variations in the spike that enhanced transmissibility or weakened vaccine protection.
Dispersal patterns and influence of air travel during the global expansion of SARS-CoV-2 variants of concern
Long-Term Dysfunction of Taste Papillae in SARS-CoV-2
COVID-19 evolving variants and how to stay safe
Why are we seeing a rising number of COVID-19 cases in some parts of the world? How is the SARS CoV 2 virus evolving? What do Governments and the public need to do to live with COVID-19 safely? Dr Maria Van Kerkhove explains in WHO's Science in 5.
SARS-CoV-2 Omicron boosting induces de novo B cell response in humans
The primary two-dose SARS-CoV-2 mRNA vaccine series are strongly immunogenic in humans, but the emergence of highly infectious variants necessitated additional doses and the development of new variant-derived vaccines.
When to update COVID-19 vaccine composition
Vaccines against different SARS-CoV-2 variants have been approved, but continued surveillance is needed to determine when the antigen composition of vaccines should be updated, together with clinical studies to assess vaccine efficacy.
Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant has been dominant in Europe since January 2022, causing large waves of infections because of high transmissibility and escape from vaccine- and infection-induced immunity.